Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation

CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S

1974 • 3,686 citations

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

2001 • 1,420 citations

Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation

1986 • 803 citations

Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

1988 • 397 citations

Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease

1986 • 275 citations

Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients

2000 • 140 citations

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

1998 • 110 citations

The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation

2000 • 105 citations

Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation.

1994 • 93 citations

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin

2001 • 81 citations

Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses

1998 • 68 citations

Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT

2000 • 61 citations

Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA‐mismatched bone marrow transplant patients

2000 • 48 citations

DEVELOPMENT OF CYTOMEGALOVIRUS RESISTANCE TO GANCICLOVIR AFTER ORAL MAINTENANCE TREATMENT IN A RENAL TRANSPLANT RECIPIENT

2000 • 33 citations